The evolution of hiv-1 interactions with coreceptors and mannose C-type lectin receptors

Progress in Molecular Biology and Translational Science

Volumn 129, Issue , 2015, Pages 109-140

  Borggren, Marie ^a   Jansson, Marianne ^b,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CCR5; CLR; Coreceptors; CXCR4; Evolution; HIV

Indexed keywords

4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOROMETHYL)PHENYL]ETHYL]PIPERAZINE; ANTIRETROVIRUS AGENT; C TYPE LECTIN RECEPTOR; CD209 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HIV 1 CORECEPTOR; LANGERIN; LECTIN; LECTIN RECEPTOR; MANNOSE C TYPE LECTIN RECEPTOR; MANNOSE RECEPTOR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; UNCLASSIFIED DRUG; VICRIVIROC; CELL SURFACE RECEPTOR; MANNOSE BINDING LECTIN; VIRUS RECEPTOR;

ANTIGEN PRESENTATION; CELL ADHESION; DENDRITIC CELL; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; VERTICAL TRANSMISSION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; VIROLOGY;

EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; RECEPTORS, CELL SURFACE; RECEPTORS, CHEMOKINE; RECEPTORS, VIRUS;

EID: 84920772149     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2014.10.004     Document Type: Chapter

References (221)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312(5996):763-767.
2. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, Gprotein-coupled receptor. Science. 1996;272(5263):872-877.
3. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667-673.
4. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85(7):1149-1158.
5. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85(7):1135-1148.
6. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology. 1997;234(2):340-348.
7. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661-666.
8. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100(5):587-597.
9. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol. 2006;6(11):859-868.
10. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;47(3):333-348.
11. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol. 1988;62(6):2026-2032.
12. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988;240(4848):80-82.
13. Asjo B, Morfeldt-Manson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986;2(8508):660-662.
14. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol. 1988;62(11):4414-4419.
15. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811-1815.
16. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature. 1998;391(6664):240.
17. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF. Chemokine (C-C motif ) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS. 2008;22(12):1425-1431.
18. Yi Y, Isaacs SN, Williams DA, et al. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J Virol. 1999;73(9):7117-7125.
19. Pollakis G, Paxton WA. Use of (alternative) coreceptors for HIV entry. Curr Opin HIV AIDS. 2012;7(5):440-449.
20. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385(6617):645-649.
21. Karlsson U, Antonsson L, Ljungberg B, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS. 2012;26(14):1739-1744.
22. Aasa-Chapman MM, Aubin K, Williams I, McKnight A. Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology. 2006;351(2):489-496.
23. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367-377.
24. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593):722-725.
25. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet. 1997;349(9060):1219.
26. Morner A, Bjorndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol. 1999;73(3):2343-2349.
27. Blaak H, Boers PH, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus AD. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol. 2005;79(3):1686-1700.
28. Neil SJ, Aasa-Chapman MM, Clapham PR, Nibbs RJ, McKnight A, Weiss RA. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol. 2005;79(15):9618-9624.
29. Loetscher P, Moser B, Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol. 2000;74:127-180.
30. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997;94(5):1925-1930.
31. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382(6594):829-833.
32. Jansson M, Popovic M, Karlsson A, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A. 1996;93(26):15382-15387.
33. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol. 1997;71(10):7478-7487.
34. Scarlatti G, Leitner T, Halapi E, et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci U S A. 1993;90(5):1721-1725.
35. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008;82(8):3952-3970.
36. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 1993;261(5125):1179-1181.
37. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94(5):2060-2067.
38. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retrovir. 2002;18(8):567-576.
39. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206(6):1273-1289.
40. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105(21):7552-7557.
41. Grivel JC, Shattock RJ, Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med. 2011;9(suppl 1):S6.
42. Meng G, Wei X, Wu X, et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med. 2002;8(2):150-156.
43. Cavarelli M, Foglieni C, Rescigno M, Scarlatti G. R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the CCR5. EMBO Mol Med. 2013;5(5):776-794.
44. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science. 1999;286(5443):1353-1357.
45. Ochsenbauer C, Edmonds TG, Ding H, et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol. 2012;86(5):2715-2728.
46. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200(6):749-759.
47. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280(5362):427-431.
48. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9(3):301-309.
49. Parrish NF, Wilen CB, Banks LB, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 2012;8(5):e1002686.
50. Harouse JM, Buckner C, Gettie A, et al. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A. 2003;100(19):10977-10982.
51. Sina ST, Ren W, Cheng-Mayer C. Coreceptor use in nonhuman primate models of HIV infection. J Transl Med. 2011;9(suppl 1):S7.
52. Scarlatti G, Hodara V, Rossi P, et al. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology. 1993;197(2):624-629.
53. Huang W, Eshleman SH, Toma J, et al. Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. AIDS. 2009;23(14):1903-1908.
54. Cavarelli M, Scarlatti G. HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection. J Transl Med. 2011;9(suppl 1):S10.
55. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol. 1994;32(2):364-370.
56. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118(9):681-688.
57. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169(5):968-974.
58. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185(4):621-628.
59. Jansson M, Backstrom E, Bjorndal A, et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol. 1999;2(6):325-338.
60. de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis. 1999;180(4):1106-1115.
61. Fenyo EM, Esbjornsson J, Medstrand P, Jansson M. Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance. J Intern Med. 2011;270(6):520-531.
62. Spijkerman IJ, Koot M, Prins M, et al. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS (London, England). 1995;9(9):1085-1092.
63. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS. 2008;22(7):896-899.
64. Esbjornsson J, Mansson F, Martinez-Arias W, et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology. 2010;7(1):23.
65. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis. 2008;198(8):1104-1112.
66. Regoes RR, Bonhoeffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol. 2005;13(6):269-277.
67. Mild M, Esbjornsson J, Fenyo EM, Medstrand P. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J Virol. 2007;81(7):3369-3376.
68. Nishimura Y, Shingai M, Lee WR, et al. Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. J Virol. 2011;85(20):10617-10626.
69. Zhuang K, Finzi A, Tasca S, et al. Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One. 2011;6(7):e21350.
70. Zhuang K, Finzi A, Toma J, et al. Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology. 2012;9:106.
71. Mild M, Gray RR, Kvist A, et al. High intrapatient HIV-1 evolutionary rate is associated with CCR5-to-CXCR4 coreceptor switch. Infect Genet Evol. 2013;19:369-377.
72. Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog. 2011;7(6):e1002106.
73. Ida S, Gatanaga H, Shioda T, et al. HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS. AIDS Res Hum Retrovir. 1997;13(18):1597-1609.
74. Raymond S, Saliou A, Delobel P, et al. Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. J Antimicrob Chemother. 2014;69(9):2527-2530.
75. Casper CH, Clevestig P, Carlenor E, et al. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis. 2002;186(7):914-921.
76. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr. 2011;56(1):9-15.
77. Borggren M, Repits J, Kuylenstierna C, et al. Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology. 2008;5:28.
78. Gray L, Sterjovski J, Churchill M, et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 2005;337(2):384-398.
79. Karlsson I, Antonsson L, Shi Y, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol. 2004;78(21):11807-11815.
80. Koning FA, Kwa D, Boeser-Nunnink B, et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 2003;188(6):864-872.
81. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis. 2003;187(9):1397-1403.
82. Mild M, Kvist A, Esbjornsson J, Karlsson I, Fenyo EM, Medstrand P. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol. 2010;10(3):356-364.
83. Repits J, Oberg M, Esbjornsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol. 2005;86(pt 10):2859-2869.
84. Repits J, Sterjovski J, Badia-Martinez D, et al. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology. 2008;379(1):125-134.
85. Sterjovski J, Churchill MJ, Ellett A, et al. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology. 2007;4:89.
86. Sterjovski J, Roche M, Churchill MJ, et al. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology. 2010;404(2):269-278.
87. Wade J, Sterjovski J, Gray L, et al. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology. 2010;396(2):246-255.
88. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium- and nonsyncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS. 1999;13(11):1305-1311.
89. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo EM. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retrovir. 1999;15(7):647-653.
90. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology. 1998;241(2):181-188.
91. Duenas-Decamp MJ, Peters PJ, Repik A, et al. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Futur Virol. 2010;5(4):435-451.
92. Antonsson L, Boketoft A, Garzino-Demo A, Olde B, Owman C. Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. AIDS. 2003;17(18):2571-2579.
93. Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS. 2003;17(18):2561-2569.
94. Zhou N, Luo Z, Hall JW, Luo J, Han X, Huang Z. Molecular modeling and site-directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction. Eur J Immunol. 2000;30(1):164-173.
95. Cavarelli M, Karlsson I, Ripamonti C, Plebani A, Fenyo EM, Scarlatti G. Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children. AIDS. 2010;24(16):2527-2533.
96. Cavarelli M, Karlsson I, Zanchetta M, et al. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS One. 2008;3(9):e3292.
97. Karlsson U, Antonsson L, Repits J, et al. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retrovir. 2009;25(12):1297-1305.
98. Parker ZF, Iyer SS, Wilen CB, et al. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol. 2013;87(5):2401-2411.
99. Borggren M, Repits J, Sterjovski J, et al. Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One. 2011;6(6):e20135.
100. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol. 2008;82(16):7932-7941.
101. Seclen E, Soriano V, Del Mar Gonzalez M, Gonzalez-Lahoz J, Poveda E. Severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions. AIDS Res Hum Retrovir. 2011;27(9):965-967.
102. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol. 1992;66(5):3183-3187.
103. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J. 2004;86(2):1234-1242.
104. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3(9):697-709.
105. Pohlmann S, Baribaud F, Lee B, et al. DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol. 2001;75(10):4664-4672.
106. Hirbod T, Kaldensjo T, Broliden K. In situ distribution of HIV-binding CCR5 and C-type lectin receptors in the human endocervical mucosa. PLoS One. 2011;6(9):e25551.
107. Hirbod T, Kaldensjo T, Lopalco L, et al. Abundant and superficial expression of C-type lectin receptors in ectocervix of women at risk of HIV infection. J Acquir Immune Defic Syndr. 2009;51(3):239-247.
108. Hirbod T, Bailey RC, Agot K, et al. Abundant expression of HIV target cells and C-type lectin receptors in the foreskin tissue of young Kenyan men. Am J Pathol. 2010;176(6):2798-2805.
109. Gurney KB, Elliott J, Nassanian H, et al. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol. 2005;79(9):5762-5773.
110. Soilleux EJ, Morris LS, Lee B, et al. Placental expression of DC-SIGN may mediate intrauterine vertical transmission of HIV. J Pathol. 2001;195(5):586-592.
111. Shen R, Smythies LE, Clements RH, Novak L, Smith PD. Dendritic cells transmit HIV-1 through human small intestinal mucosa. J Leukoc Biol. 2010;87(4):663-670.
112. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 2002;16(1):135-144.
113. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog. 2007;3(1):e4.
114. Yu HJ, Reuter MA, McDonald D. HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog. 2008;4(8):e1000134.
115. Burleigh L, Lozach PY, Schiffer C, et al. Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J Virol. 2006;80(6):2949-2957.
116. Nobile C, Petit C, Moris A, et al. Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes. J Virol. 2005;79(9):5386-5399.
117. Turville SG, Santos JJ, Frank I, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood. 2004;103(6):2170-2179.
118. Hijazi K, Wang Y, Scala C, et al. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. PLoS One. 2011;6(12):e28307.
119. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol. 2010;11(5):419-426.
120. van der Vlist M, van der Aar AM, Gringhuis SI, Geijtenbeek TB. Innate signaling in HIV-1 infection of dendritic cells. Curr Opin HIV AIDS. 2011;6(5):348-352.
121. Soilleux EJ, Barten R, Trowsdale J. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J Immunol. 2000;165(6):2937-2942.
122. Pohlmann S, Soilleux EJ, Baribaud F, et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A. 2001;98(5):2670-2675.
123. Engering A, van Vliet SJ, Hebeda K, et al. Dynamic populations of dendritic cell-specific ICAM-3 grabbing nonintegrin-positive immature dendritic cells and liver/lymph node-specific ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the paracortex of human lymph nodes. Am J Pathol. 2004;164(5):1587-1595.
124. Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101(44):15748-15753.
125. Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science. 2001;294(5549):2163-2166.
126. Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, et al. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med. 2001;193(6):671-678.
127. Snyder GA, Ford J, Torabi-Parizi P, et al. Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor's role as an antigen-capturing rather than an adhesion receptor. J Virol. 2005;79(8):4589-4598.
128. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity. 2007;26(2):257-270.
129. Turville SG, Cameron PU, Handley A, et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol. 2002;3(10):975-983.
130. Holla A, Skerra A. Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin. Protein Eng Des Sel. 2011;24(9):659-669.
131. de Witte L, Nabatov A, Pion M, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med. 2007;13(3):367-371.
132. Ballweber L, Robinson B, Kreger A, et al. Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells. J Virol. 2011;85(24):13443-13447.
133. Kawamura T, Gulden FO, Sugaya M, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A. 2003;100(14):8401-8406.
134. Peressin M, Holl V, Schmidt S, et al. HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J Virol. 2011;85(2):1077-1085.
135. Fanibunda SE, Modi DN, Gokral JS, Bandivdekar AH. HIV gp120 binds to mannose receptor on vaginal epithelial cells and induces production of matrix metalloproteinases. PLoS One. 2011;6(11):e28014.
136. Jadhav SK, Velhal SM, Deshpande A, Bandivdekar AH. Association of human mannose receptor in sexual transmission of human immunodeficiency virus in serodiscordant couples. AIDS Res Hum Retrovir. 2013;29(1):156-163.
137. Nguyen DG, Hildreth JE. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol. 2003;33(2):483-493.
138. Trujillo JR, Rogers R, Molina RM, et al. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci US A. 2007;104(12):5097-5102.
139. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood. 2008;112(4):1299-1307.
140. Lambert AA, Barabe F, Gilbert C, Tremblay MJ. DCIR-mediated enhancement of HIV-1 infection requires the ITIM-associated signal transduction pathway. Blood. 2011;117(24):6589-6599.
141. Lambert AA, Imbeault M, Gilbert C, Tremblay MJ. HIV-1 induces DCIR expression in CD4+ T cells. PLoS Pathog. 2010;6(11):e1001188.
142. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood. 2008;111(8):4245-4253.
143. Meyer-Wentrup F, Cambi A, Joosten B, et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol. 2009;85(3):518-525.
144. Chaipan C, Soilleux EJ, Simpson P, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol. 2006;80(18):8951-8960.
145. Hatsukari I, Singh P, Hitosugi N, et al. DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J Am Soc Nephrol. 2007;18(3):780-787.
146. Mikulak J, Teichberg S, Faust T, Schmidtmayerova H, Singhal PC. HIV-1 harboring renal tubular epithelial cell interaction with T cells results in T cell trans-infection. Virology. 2009;385(1):105-114.
147. de Witte L, de Vries RD, van der Vlist M, et al. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog. 2008;4(4):e1000049.
148. Engering A, Van Vliet SJ, Geijtenbeek TB, Van Kooyk Y. Subset of DC-SIGN(+) dendritic cells in human blood transmits HIV-1 to T lymphocytes. Blood. 2002;100(5):1780-1786.
149. Jameson B, Baribaud F, Pohlmann S, et al. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol. 2002;76(4):1866-1875.
150. Kaldensjo T, Petersson P, Tolf A, Morgan G, Broliden K, Hirbod T. Detection of intraepithelial and stromal Langerin and CCR5 positive cells in the human endometrium: potential targets for HIV infection. PLoS One. 2011;6(6):e21344.
151. Lore K, Sonnerborg A, Brostrom C, et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS. 2002;16(5):683-692.
152. te Velde AA, van Kooyk Y, Braat H, et al. Increased expression of DC-SIGN+IL-12 +IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol. 2003;33(1):143-151.
153. Boily-Larouche G, Milev MP, Zijenah LS, et al. Naturally-occurring genetic variants in human DC-SIGN increase HIV-1 capture, cell-transfer and risk of mother-to-child transmission. PLoS One. 2012;7(7):e40706.
154. Boily-Larouche G, Iscache AL, Zijenah LS, et al. Functional genetic variants in DC-SIGNR are associated with mother-to-child transmission of HIV-1. PLoS One. 2009;4(10):e7211.
155. da Silva RC, Segat L, Zanin V, Arraes LC, Crovella S. Polymorphisms in DC-SIGN and L-SIGN genes are associated with HIV-1 vertical transmission in a Northeastern Brazilian population. Hum Immunol. 2012;73(11):1159-1165.
156. Borggren M, Naver L, Casper C, Ehrnst A, Jansson M. R5 human immunodeficiency virus type 1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children. J Gen Virol. 2013;94(pt 4):767-773.
157. Baan E, de Ronde A, Stax M, et al. HIV-1 autologous antibody neutralization associates with mother to child transmission. PLoS One. 2013;8(7):e69274.
158. Martin MP, Lederman MM, Hutcheson HB, et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol. 2004;78(24):14053-14056.
159. Selvaraj P, Alagarasu K, Swaminathan S, Harishankar M, Narendran G. CD209 gene polymorphisms in South Indian HIV and HIV-TB patients. Infect Genet Evol. 2009;9(2):256-262.
160. Li H, Yu XM, Wang JX, Hong ZH, Tang NL. The VNTR polymorphism of the DC-SIGNR gene and susceptibility to HIV-1 infection: a meta-analysis. PLoS One. 2012;7(9):e42972.
161. Wichukchinda N, Kitamura Y, Rojanawiwat A, et al. The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retrovir. 2007;23(5):686-692.
162. Zhu D, Kawana-Tachikawa A, Iwamoto A, Kitamura Y. Influence of polymorphism in dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related (DC-SIGNR) gene on HIV-1 trans-infection. Biochem Biophys Res Commun. 2010;393(4):598-602.
163. Groot F, Geijtenbeek TB, Sanders RW, et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol. 2005;79(5):3009-3015.
164. Hong P, Ninonuevo MR, Lee B, Lebrilla C, Bode L. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101(4):482-486.
165. Naarding MA, Dirac AM, Ludwig IS, et al. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. Antimicrob Agents Chemother. 2006;50(10):3367-3374.
166. Naarding MA, Ludwig IS, Groot F, et al. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest. 2005;115(11):3256-3264.
167. Requena M, Bouhlal H, Nasreddine N, et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRDdomain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology. 2008;123(4):508-518.
168. Saeland E, de Jong MA, Nabatov AA, Kalay H, Geijtenbeek TB, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol. 2009;46(11-12):2309-2316.
169. Stax MJ, Naarding MA, Tanck MW, et al. Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One. 2011;6(2):e17316.
170. Yagi Y, Watanabe E, Watari E, et al. Inhibition of DC-SIGN-mediated transmission of human immunodeficiency virus type 1 by Toll-like receptor 3 signalling in breast milk macrophages. Immunology. 2010;130(4):597-607.
171. Sabatte J, Faigle W, Ceballos A, et al. Semen clusterin is a novel DC-SIGN ligand. J Immunol. 2011;187(10):5299-5309.
172. Stax MJ, van Montfort T, Sprenger RR, et al. Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology. 2009;391(2):203-211.
173. Vazquez-Guillen JM, Garcia-Jacobo PJ, Zapata-Benavides P, et al. Expression of DC-SIGN in peripheral blood dendritic cells of patients with typical, slow, and rapid progression to AIDS. Arch Med Res. 2009;40(2):132-135.
174. van Montfort T, Nabatov AA, Geijtenbeek TB, Pollakis G, Paxton WA. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. J Immunol. 2007;178(5):3177-3185.
175. Marzi A, Mitchell DA, Chaipan C, et al. Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology. 2007;368(2):322-330.
176. Ganesh L, Leung K, Lore K, et al. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol. 2004;78(21):11980-11987.
177. van Montfort T, Eggink D, Boot M, et al. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J Immunol. 2011;187(9):4676-4685.
178. Lue J, Hsu M, Yang D, Marx P, Chen Z, Cheng-Mayer C. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol. 2002;76(20):10299-10306.
179. Nabatov AA, van Montfort T, Geijtenbeek TB, Pollakis G, Paxton WA. Interaction of HIV-1 with dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-expressing cells is influenced by gp120 envelope modifications associated with disease progression. FEBS J. 2006;273(21):4944-4958.
180. van Montfort T, Thomas AA, Pollakis G, Paxton WA. Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans. J Virol. 2008;82(16):7886-7896.
181. Koizumi Y, Kageyama S, Fujiyama Y, et al. RANTES - 28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res Hum Retrovir. 2007;23(5):713-719.
182. Stax MJ, Kootstra NA. van 't Wout AB, et al. HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism. PLoS One. 2012;7(3):e32534.
183. MacArthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008;47(2):236-241.
184. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol. 2008;73(3):789-800.
185. Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs. 2010;70(9):1189-1213.
186. Raymond S, Delobel P, Izopet J. Phenotyping methods for determining HIV tropism and applications in clinical settings. Curr Opin HIV AIDS. 2012;7(5):463-469.
187. Obermeier M, Symons J, Wensing AM. HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS. 2012;7(5):470-477.
188. Archer J, Weber J, Henry K, et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One. 2012;7(11):e49602.
189. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359(14):1442-1455.
190. Symons J, van Lelyveld SF, Hoepelman AI, et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother. 2010;66(4):890-895.
191. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS. 2009;4(2):118-124.
192. Westby M. Resistance to CCR5 antagonists. Curr Opin HIV AIDS. 2007;2(2):137-144.
193. Roche M, Salimi H, Duncan R, et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology. 2013;10:43.
194. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009;5(8):e1000548.
195. Ogert RA, Ba L, Hou Y, et al. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol. 2009;83(23):12151-12163.
196. Tilton JC, Wilen CB, Didigu CA, et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol. 2010;84(20):10863-10876.
197. Wang SK, Liang PH, Astronomo RD, et al. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A. 2008;105(10):3690-3695.
198. Luallen RJ, Fu H, Agrawal-Gamse C, et al. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol. 2009;83(10):4861-4870.
199. Martinez-Avila O, Hijazi K, Marradi M, et al. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chemistry. 2009;15(38):9874-9888.
200. Becer CR, Gibson MI, Geng J, et al. High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein. J Am Chem Soc. 2010;132(43):15130-15132.
201. Martinez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcami J, Penades S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. Chembiochem. 2009;10(11):1806-1809.
202. Sattin S, Daghetti A, Thepaut M, et al. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation. ACS Chem Biol. 2010;5(3):301-312.
203. Berzi A, Reina JJ, Ottria R, et al. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. AIDS. 2012;26(2):127-137.
204. Balzarini J, Francois KO, Van Laethem K, et al. Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob Agents Chemother. 2010;54(4):1425-1435.
205. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol. 2007;71(1):3-11.
206. Bertaux C, Daelemans D, Meertens L, et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007;366(1):40-50.
207. Hoorelbeke B, Van Damme EJ, Rouge P, et al. Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity. Retrovirology. 2011;8(1):10.
208. Alexandre KB, Gray ES, Mufhandu H, et al. The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology. 2012;423(2):175-186.
209. Turville SG, Vermeire K, Balzarini J, Schols D. Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer. J Virol. 2005;79(21):13519-13527.
210. Balzarini J, Van Laethem K, Hatse S, et al. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol. 2004;78(19):10617-10627.
211. Balzarini J, Van Laethem K, Hatse S, et al. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV. J Biol Chem. 2005;280(49):41005-41014.
212. Balzarini J, Van Laethem K, Hatse S, et al. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. Mol Pharmacol. 2005;67(5):1556-1565.
213. Balzarini J, Van Laethem K, Peumans WJ, et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol. 2006;80(17):8411-8421.
214. Balzarini J. The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett. 2007;581(10):2060-2064.
215. Witvrouw M, Fikkert V, Hantson A, et al. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol. 2005;79(12):7777-7784.
216. Balzarini J, Van Laethem K, Daelemans D, et al. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J Virol. 2007;81(1):362-373.
217. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med. 1998;4(6):679-684.
218. Kang SM, Quan FS, Huang C, et al. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology. 2005;331(1):20-32.
219. Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, Olofsson S. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine. 2001;20(3-4):397-405.
220. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol. 2007;5(8):583-597.
221. Francois KO, Balzarini J. Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev. 2012;32(2):349-387.